Guardant Health Highlights Broad Liquid Biopsy Research Portfolio at ESMO Congress 2026
Business Wire•20/10/2026•09:02 ET
0
Key Highlights
- ➤25 ESMO 2026 abstracts, including five rapid oral presentations, showcase Guardant’s liquid biopsy research
- ➤Studies span lung, colorectal, and gastric cancers, covering MRD, treatment response, and resistance
- ➤NADIM II analysis links MRD negativity with favorable long-term outcomes after perioperative nivolumab
- ➤Guardant expands European public-private partnerships with Royal Marsden, Vall d’Hebron, and Policlinico Gemelli
Expert Statements
Helmy Eltoukhy, Chairman and co-CEO of Guardant Health
“At ESMO, we will showcase how InfinityAI is advancing our portfolio, strengthening the clinical relevance of our data, and delivering value to patients, healthcare professionals, and biopharma partners.”
Helmy Eltoukhy, Chairman and co-CEO of Guardant Health
“We look forward to presenting new findings and connecting with the oncology community to discuss how Guardant’s solutions can advance cancer care globally.”
Guardant Health Highlights Broad Liquid Biopsy Research Portfolio at ESMO Congress 2026
* Research reinforces the significance of genomic and epigenomic profiling approaches to characterize tumor types, identify biomarkers, and support risk stratification
Get started
Create a free account to read the full story.